Literature DB >> 7906266

3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin.

S Rao1, N E Krauss, J M Heerding, C S Swindell, I Ringel, G A Orr, S B Horwitz.   

Abstract

Taxol possesses an unusual chemical structure, a unique mechanism of action, and demonstrated activity in human malignancies. It is the only antitumor agent that has a binding site on the microtubule polymer. The interaction of Taxol with the microtubule polymer results in the formation of stable bundles of cellular microtubules that are resistant to depolymerization. Although it has become evident that the microtubule, specifically beta-tubulin, is the target for Taxol, no information is available on the binding site for the drug. In this report, we demonstrate that 3'-(p-azidobenzamido)taxol, an analogue with similar biological activities as Taxol, covalently binds to the N-terminal domain of beta-tubulin after irradiation of the microtubule-drug complex. Taxol competes with [3H]3'-(p-azidobenzamido)-taxol binding, suggesting that the photoaffinity analog and Taxol are binding at the same or overlapping sites. Formic acid cleavage of [3H]3'-(p-azidobenzamido)-taxol-photolabeled beta-tubulin and subsequent protein sequence and mass analyses have identified the N-terminal 31 amino acids as the major site for [3H]3'-(p-azidobenzamido)taxol photoincorporation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7906266

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density.

Authors:  J P Snyder; J H Nettles; B Cornett; K H Downing; E Nogales
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

2.  The N-terminal 34 residues of the 55 kDa regulatory subunits of phosphoinositide 3-kinase interact with tubulin.

Authors:  K Inukai; M Funaki; M Nawano; H Katagiri; T Ogihara; M Anai; Y Onishi; H Sakoda; H Ono; Y Fukushima; M Kikuchi; Y Oka; T Asano
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

3.  The cofactor-dependent pathways for alpha- and beta-tubulins in microtubule biogenesis are functionally different in fission yeast.

Authors:  P A Radcliffe; M A Garcia; T Toda
Journal:  Genetics       Date:  2000-09       Impact factor: 4.562

4.  Design and synthesis of simplified taxol analogs based on the T-Taxol bioactive conformation.

Authors:  Jielu Zhao; Susan Bane; James P Snyder; Haipeng Hu; Kamalika Mukherjee; Carla Slebodnick; David G I Kingston
Journal:  Bioorg Med Chem       Date:  2011-10-13       Impact factor: 3.641

Review 5.  Mechanisms of Taxol resistance related to microtubules.

Authors:  George A Orr; Pascal Verdier-Pinard; Hayley McDaid; Susan Band Horwitz
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

6.  Profile of Susan Band Horwitz.

Authors:  Tinsley H Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

7.  Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer.

Authors:  Ginah Nightingale; Jae Ryu
Journal:  P T       Date:  2012-08

8.  Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity.

Authors:  A L Risinger; J Li; M J Bennett; C C Rohena; J Peng; D C Schriemer; S L Mooberry
Journal:  Cancer Res       Date:  2013-09-18       Impact factor: 12.701

9.  Total synthesis and evaluation of C26-hydroxyepothilone D derivatives for photoaffinity labeling of beta-tubulin.

Authors:  Emily A Reiff; Sajiv K Nair; John T Henri; Jack F Greiner; Bollu S Reddy; Ramappa Chakrasali; Sunil A David; Ting-Lan Chiu; Elizabeth A Amin; Richard H Himes; David G Vander Velde; Gunda I Georg
Journal:  J Org Chem       Date:  2010-01-01       Impact factor: 4.354

Review 10.  Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?

Authors:  J Thomas De Ligio; Aneliya Velkova; Diego A R Zorio; Alvaro N A Monteiro
Journal:  Anticancer Agents Med Chem       Date:  2009-06       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.